Actinium Pharmaceuticals Inc (ATNM)
AMEXHealth CareBiotechnologySnapshot 2026-11-05
$1.30-7.80%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ATNM
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
NYSE American Listing Update Actinium also announced today that NYSE Regulation has accepted the Company’s plan submitted June 18, 2026, to regain compliance with the NYSE American continued listing…
Stated in 1 of 1 supplied quarters. Management reported: “NYSE American Listing Update Actinium also announced today that NYSE Regulation has accepted the Company’s plan submitted June 18, 2026, to regain compliance with the NYSE American continued listing standards and granted the Company a plan period through November 27, 2027 (the “Plan Period”) - the maximum period available under Section 1009 of the NYSE American Company Guide (the “Company Guide”).” “As of March 31, 2026, the Company reported stockholders’ equity of approximately $2.3 million and had net losses in its last five fiscal years ended December 31, 2025.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“NYSE American Listing Update Actinium also announced today that NYSE Regulation has accepted the Company’s plan submitted June 18, 2026, to regain compliance with the NYSE American continued listing…”
The additional manufacturer will supply studies conducted under the Company’s Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), together with additional…
Stated in 1 of 1 supplied quarters. Management reported: “Exhibit 99.1 Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update NEW YORK, August 14, 2026 /PRNewswire/ – Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company’s manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 and into 2027.”
“The additional manufacturer will supply studies conducted under the Company’s Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), together with additional…”
Establishing an additional manufacturing source is intended to expand capacity and supply flexibility as Actimab-A advances into a broader set of studies across hematologic malignancies and solid tum…
Stated in 1 of 1 supplied quarters. Management reported: “Establishing an additional manufacturing source is intended to expand capacity and supply flexibility as Actimab-A advances into a broader set of studies across hematologic malignancies and solid tumors.” “Actinium has amended its Investigational New Drug (IND) application to add an additional manufacturer.”
“Establishing an additional manufacturing source is intended to expand capacity and supply flexibility as Actimab-A advances into a broader set of studies across hematologic malignancies and solid tum…”
Advance ATNM-400 and Actimab-A through clinical development, including Actimab-A studies with the National Cancer Institute.
Focus on improving operating income and net income to achieve profitability after prior losses.
Over the trailing year it converted 0.72x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
8 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.